The document lists 33 publications related to the preparation and testing of compounds that modulate cannabinoid receptors and inhibit kynurenine-3-monooxygenase. Many of the publications involve authors Celia Dominguez, Leticia Toledo-Sherman, Michael Prime, and William Mitchell. The publications span from 2005 to 2015 and include patents, journal articles, and conference presentations on developing therapies for neurodegenerative disorders and pain treatment.
Jennifer M. Sealy has authored or co-authored several publications including papers in peer-reviewed journals and patents. Some of her notable publications include papers in Bioorganic & Medicinal Chemistry Letters on the design and synthesis of brain penetrant JNK inhibitors for neurodegeneration prevention, and on the design of hydroxyethylamine BACE-1 inhibitors for Alzheimer's disease. She is also listed as an inventor on several patents related to the preparation of inhibitors for conditions like Alzheimer's.
This document provides a list of publications by Jennifer M. Sealy including 10 papers published in Bioorganic & Medicinal Chemistry Letters between 2010-2011 related to the design and synthesis of inhibitors for neurodegeneration. It also lists 4 patents with Sealy as an inventor related to the preparation of inhibitors for treating conditions like Alzheimer's disease.
This document provides a summary of Olivier Grenet's scientific publications, patents, and presentations. It includes 18 peer-reviewed publications, many focusing on using omics technologies like microarrays and real-time PCR to study drug-induced changes in gene expression. It also lists several patents related to predictive biomarkers for drug toxicity and clinical response. Grenet has given numerous invited talks on applying genomics and pharmacogenomics in drug development to improve safety evaluation and clinical translation.
The laboratory focuses on developing drug delivery systems using biomaterials like hyaluronic acid. A thermosensitive injectable hydrogel was created using nanocomplexes of doxorubicin and hyaluronic acid for local cancer treatment. This hydrogel inhibited cancer cell growth and selectively targeted the lymphatic system due to hyaluronic acid's affinity for the lymphatic system. The lab is also exploring combination therapy delivery systems, such as a thermosensitive hydrogel incorporating doxorubicin and docetaxel-loaded nanoparticles for overcoming drug resistance in tumors.
This document provides a bibliography of 45 peer-reviewed publications by Dr. Finlay between 1978-1993. The publications cover a range of topics including bone marrow transplantation, leukemia, brain tumors, and other pediatric oncology issues. Many of the publications involve clinical trials and case studies conducted at the Children's Hospital of Philadelphia where Dr. Finlay worked.
This document provides an overview of chronic granulomatous disease (CGD), including its history, epidemiology, pathogenesis, and clinical features. CGD is a primary immunodeficiency caused by defects in the NADPH oxidase complex that generates superoxide in phagocytes. This impairs the ability to kill certain bacteria and fungi, leading to life-threatening infections. The condition was first described in the 1950s and genetic causes involving mutations in CYBB, CYBA, NCF1, NCF2, and NCF4 genes that encode phagocyte oxidase subunits were identified starting in the 1980s. CGD has an incidence of approximately 1 in 200,000 individuals.
This document provides an overview of Autoimmune Polyendocrinopathy-Candidiasis–Ectodermal Dysplasia (APECED), also known as Autoimmune Polyendocrinopathy Syndrome Type 1 (APS-1). It discusses the epidemiology, pathogenesis, clinical manifestations, diagnosis, and management. The pathogenesis involves mutations in the autoimmune regulator (AIRE) gene leading to loss of central tolerance and autoimmunity against various endocrine and other tissues. Common clinical manifestations include chronic mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency, and others. Diagnosis is based on clinical criteria and AIRE gene mutation analysis can confirm. Management requires treatment of
This document provides a list of publications and patents by Christopher J. Aquino related to drug discovery across several therapeutic areas, including diabetes/obesity, cancer, HIV, and obesity. The list includes over 50 publications describing Aquino's work discovering and developing inhibitors of the ileal bile acid transporter, fatty acid synthase, CCR5 chemokine receptor, and reverse transcriptase for various indications. Additional publications cover Aquino's research on neuropeptide YY5 antagonists for obesity and cholecystokinin receptor agonists/antagonists for obesity and cancer.
Jennifer M. Sealy has authored or co-authored several publications including papers in peer-reviewed journals and patents. Some of her notable publications include papers in Bioorganic & Medicinal Chemistry Letters on the design and synthesis of brain penetrant JNK inhibitors for neurodegeneration prevention, and on the design of hydroxyethylamine BACE-1 inhibitors for Alzheimer's disease. She is also listed as an inventor on several patents related to the preparation of inhibitors for conditions like Alzheimer's.
This document provides a list of publications by Jennifer M. Sealy including 10 papers published in Bioorganic & Medicinal Chemistry Letters between 2010-2011 related to the design and synthesis of inhibitors for neurodegeneration. It also lists 4 patents with Sealy as an inventor related to the preparation of inhibitors for treating conditions like Alzheimer's disease.
This document provides a summary of Olivier Grenet's scientific publications, patents, and presentations. It includes 18 peer-reviewed publications, many focusing on using omics technologies like microarrays and real-time PCR to study drug-induced changes in gene expression. It also lists several patents related to predictive biomarkers for drug toxicity and clinical response. Grenet has given numerous invited talks on applying genomics and pharmacogenomics in drug development to improve safety evaluation and clinical translation.
The laboratory focuses on developing drug delivery systems using biomaterials like hyaluronic acid. A thermosensitive injectable hydrogel was created using nanocomplexes of doxorubicin and hyaluronic acid for local cancer treatment. This hydrogel inhibited cancer cell growth and selectively targeted the lymphatic system due to hyaluronic acid's affinity for the lymphatic system. The lab is also exploring combination therapy delivery systems, such as a thermosensitive hydrogel incorporating doxorubicin and docetaxel-loaded nanoparticles for overcoming drug resistance in tumors.
This document provides a bibliography of 45 peer-reviewed publications by Dr. Finlay between 1978-1993. The publications cover a range of topics including bone marrow transplantation, leukemia, brain tumors, and other pediatric oncology issues. Many of the publications involve clinical trials and case studies conducted at the Children's Hospital of Philadelphia where Dr. Finlay worked.
This document provides an overview of chronic granulomatous disease (CGD), including its history, epidemiology, pathogenesis, and clinical features. CGD is a primary immunodeficiency caused by defects in the NADPH oxidase complex that generates superoxide in phagocytes. This impairs the ability to kill certain bacteria and fungi, leading to life-threatening infections. The condition was first described in the 1950s and genetic causes involving mutations in CYBB, CYBA, NCF1, NCF2, and NCF4 genes that encode phagocyte oxidase subunits were identified starting in the 1980s. CGD has an incidence of approximately 1 in 200,000 individuals.
This document provides an overview of Autoimmune Polyendocrinopathy-Candidiasis–Ectodermal Dysplasia (APECED), also known as Autoimmune Polyendocrinopathy Syndrome Type 1 (APS-1). It discusses the epidemiology, pathogenesis, clinical manifestations, diagnosis, and management. The pathogenesis involves mutations in the autoimmune regulator (AIRE) gene leading to loss of central tolerance and autoimmunity against various endocrine and other tissues. Common clinical manifestations include chronic mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency, and others. Diagnosis is based on clinical criteria and AIRE gene mutation analysis can confirm. Management requires treatment of
This document provides a list of publications and patents by Christopher J. Aquino related to drug discovery across several therapeutic areas, including diabetes/obesity, cancer, HIV, and obesity. The list includes over 50 publications describing Aquino's work discovering and developing inhibitors of the ileal bile acid transporter, fatty acid synthase, CCR5 chemokine receptor, and reverse transcriptase for various indications. Additional publications cover Aquino's research on neuropeptide YY5 antagonists for obesity and cholecystokinin receptor agonists/antagonists for obesity and cancer.
Jeffrey J. Whyte is a researcher who has published extensively on topics related to swine genetics, cloning, and using pig models for human diseases. Some of his publications include studies looking at using zinc finger nucleases and CRISPR to genetically modify pigs, producing cloned knockout pig models, and investigating cytokines and placental development in pigs. He has also researched using pig models to study cardiovascular conditions in humans.
This curriculum vitae summarizes the educational and professional background of Todd H. Ahern, PhD. It includes his postdoctoral training at the University of Massachusetts, Amherst, and PhD from Emory University. Dr. Ahern is currently an Assistant Professor at Quinnipiac University where he teaches courses in psychology and neuroscience. His research focuses on how early life social environments influence long-term social behaviors using rodent models like prairie voles. He has published several peer-reviewed articles and mentored numerous undergraduate students in his research laboratory.
1) The document discusses vitamin D deficiency and its link to various health issues. It reports that 61-82% of postmenopausal women and 98% of patients with osteoporotic fractures have inadequate vitamin D levels.
2) Several causes of vitamin D deficiency in the elderly are described, including lack of sun exposure and less effective vitamin D synthesis in the skin.
3) The text reviews results from studies that show vitamin D supplementation can reduce fracture risk by 33%, falling risk by 49%, and improve lower limb function. It is suggested that maintaining higher vitamin D levels may provide significant economic savings in healthcare costs.
Research on Multiple Chemical Sensitivity - Resources for Healthy Children www.scribd.com/doc/254613619 - For more information, Please see Organic Edible Schoolyards & Gardening with Children www.scribd.com/doc/254613963 - Gardening with Volcanic Rock Dust www.scribd.com/doc/254613846 - Double Food Production from your School Garden with Organic Tech www.scribd.com/doc/254613765 - Free School Gardening Art Posters www.scribd.com/doc/254613694 - Increase Food Production with Companion Planting in your School Garden www.scribd.com/doc/254609890 - Healthy Foods Dramatically Improves Student Academic Success www.scribd.com/doc/254613619 - City Chickens for your Organic School Garden www.scribd.com/doc/254613553 - Huerto Ecológico, Tecnologías Sostenibles, Agricultura Organica www.scribd.com/doc/254613494 - Simple Square Foot Gardening for Schools - Teacher Guide www.scribd.com/doc/254613410 - Free Organic Gardening Publications www.scribd.com/doc/254609890 ~
Nearly 1.4 million individuals suffer from traumatic brain injury (TBI) each year, leaving many survivors with significant deficits. Early and adequate nutrition support is challenging but may improve outcomes for TBI patients. The document discusses the metabolic and immune alterations caused by TBI and recommends enteral nutrition over parenteral nutrition when possible. It emphasizes starting nutrition within 48 hours and achieving full caloric needs by day 7 to prevent protein breakdown and support recovery. Barriers to providing nutrition like feeding intolerance are also reviewed.
Nearly 1.4 million individuals suffer from traumatic brain injury (TBI) each year, leaving many survivors with significant deficits. Early and adequate nutrition support is challenging but may improve outcomes for TBI patients. The document discusses the metabolic and immune alterations caused by TBI and recommends enteral nutrition over parenteral nutrition when possible. It emphasizes starting nutrition within 48 hours and achieving full caloric needs by day 7 to prevent protein breakdown and support recovery. Barriers to providing nutrition like feeding intolerance are also reviewed.
The document discusses the possible causes of rheumatoid arthritis (RA) based on research evidence. The immune system, specifically the innate immune response involving macrophages and dendritic cells, plays an important role in the development of RA by causing inflammation and destroying joints. Genetics also contribute, as RA has been linked to chromosome 6. Some studies have found historical evidence suggesting an infectious agent may promote RA. Environmental factors like smoking, low vitamin D levels, diet, and cold weather have also been associated with increased risk or severity of RA. Understanding the causes of RA could help improve treatment and management of the disease.
This document lists 21 publications and abstracts authored by Nino G. Joy, MD. The publications focus on research investigating the effects of hypoglycemia and hyperglycemia on markers of endothelial function, inflammation, and atherothrombosis in both healthy individuals and those with diabetes. Many of the studies examine the acute physiological responses to induced hypoglycemic or hyperglycemic conditions. The publications span the years 2010 to 2016 and were published in journals like Diabetes, the Journal of Diabetes Complications, and Metabolism.
Stress is defined as a state of physiological or psychological strain caused by an adverse stimuli , physical, mental, or emotional, internal or external that tend to disturb the functioning of an organism and which the organism naturally desires to avoid.
This document discusses possible links between vitamin D deficiency and various geriatric syndromes and common comorbidities. It begins by outlining how vitamin D receptors are present in many tissues beyond the musculoskeletal system. It then examines potential associations between vitamin D deficiency and increased risks of frailty, urinary incontinence, dementia/cognitive impairment, and depression in elderly populations. While evidence is limited and relationships are not clearly causal, several observational studies have found correlations between low vitamin D levels and higher rates of these conditions. More research is still needed, but maintaining adequate vitamin D status may help reduce risks of age-related diseases and functional decline.
Ibogaine is a psychoactive substance found in plants that has been studied for its effects in treating addiction. The most researched effect is its ability to reduce or eliminate addiction to opioids by alleviating withdrawal symptoms. Research also indicates it may be useful for treating alcohol, methamphetamine and nicotine addiction, as well as compulsive behaviors. However, more systematic clinical research is still needed. Some organizations like MAPS are studying ibogaine's long term effects and safety through observational studies. Ibogaine treatment is accompanied by counseling and potential relapse requires multiple treatment sessions over 12-18 months. Ibogaine carries some risks but may help address the unmet need for effective addiction treatments.
This document summarizes research on primary immunodeficiencies that cause increased susceptibility to fungal infections. It describes how innate and adaptive immunity normally defend against fungi through pattern recognition receptors, cytokines, and T cell responses. Deficiencies in the CARD9 protein, STAT1 and STAT3 genes, and the IL-17 and IL-22 pathways are highlighted as causing chronic mucocutaneous candidiasis by impairing Th17 responses. Autoantibodies against IL-17 and IL-22 in autoimmune polyendocrine syndrome type I can also phenocopy these genetic defects. Understanding these immunodeficiencies provides insight into antifungal immunity and opportunities for new therapies.
Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphoryla...Mahmoud Lotfy Soliman
Caffeine may help reduce Alzheimer's disease pathology associated with HIV infection by blocking the effects of the HIV protein Tat. The study found that:
1) HIV Tat increased amyloid-beta and phosphorylated tau levels in neural cells, markers of Alzheimer's disease, but caffeine prevented these increases.
2) HIV Tat disrupted endolysosome function in neural cells, but caffeine blocked these effects of Tat and preserved normal endolysosome functioning.
3) Caffeine on its own decreased amyloid-beta levels and may help protect against Alzheimer's disease progression in people living with HIV through its effects on endolysosome function and Tat protein activity.
Vitamina D ed Asma - Prof. Boner Attilio Università di VeronaRoberto Conte
1) Several studies show high rates of vitamin D deficiency and insufficiency among children with asthma. Low vitamin D levels are associated with worse asthma control, including increased exacerbations and hospitalizations.
2) Observational studies link higher maternal vitamin D intake during pregnancy to lower rates of wheezing and asthma in offspring. However, the evidence for a causal relationship is still insufficient.
3) Maintaining adequate vitamin D levels, especially during pregnancy and childhood, may help reduce asthma risk and severity by supporting lung development and function. Further research is still needed.
This document lists 48 original publications by JC Möller and collaborators related to Parkinson's disease, multiple system atrophy, restless legs syndrome, and other movement disorders. The publications cover a range of topics including experimental pain sensitivity, clinical decision making tools for chronic pain patients, roles of cortical and pallidal brain frequencies, association between sleep and dyskinesia in an animal model of Parkinson's, and several genetic studies related to various movement disorders.
Endocrine Disruption and Immune DysfunctionDES Daughter
by the Collaborative on Health and the Environment
On this first in a series of calls on endocrine disrupting chemicals, Dr. Rodney Dietert discussed how the immune system is a target for endocrine disrupting chemicals, particularly during development. Numerous relatively ‘hidden’ effects can ensue from a single risk factor and emerge over a lifetime. He also discussed how current safety testing fails to appropriately assess misregulated inflammation as the greatest immune based health risk.
Sources: http://www.healthandenvironment.org/partnership_calls/13389
This webinar discusses immunometabolism and its relationship to COVID-19. It explores how elevated glucose levels can favor SARS-CoV-2 infection by inducing viral replication and cytokine expression through a HIF-1α/glycolysis pathway. Insulin treatment is also discussed and its association with increased mortality in COVID-19 patients with diabetes. The role of mitochondria in producing reactive oxygen species during infection is covered, as is the potential for antioxidants and dietary changes like ketogenic diets to impact the immune response. Biomarkers of immunometabolism are proposed for monitoring clinical outcomes.
1. The document lists 29 publications with the author Lu Y, demonstrating their expertise in biomedical research related to neurodegenerative diseases and therapeutic antibody development.
2. Many of the publications focus on characterizing antibody delivery across the blood-brain barrier and targeting proteins involved in diseases like Alzheimer's.
3. The publications span from 2004 to the present and represent collaborative work with numerous co-authors investigating topics like antibody pharmacokinetics and biomarkers.
This document is a curriculum vitae for Dr. Avi L. Friedlich summarizing his personal and educational background, academic positions held, research support and medical certification, professional memberships, honors and awards, publications, and editorial experience. It details that he received a B.S. from UCLA and an M.D. from Case Western Reserve University, held various academic and research positions at institutions including Harvard Medical School and MIT, has over 50 publications in peer-reviewed journals, and has received several honors and awards for his research work.
This document lists invited presentations, publications, and patent applications by Rikki Alexander related to pharmaceutical research. It includes presentations on phosphodiesterase inhibitors for asthma treatment from 2002-2003. It also lists several patent applications and publications from 2008-2015 on small molecule inhibitors for conditions like TNF activity and PI3 kinase. The publications involve collaborations and are focused on developing drug candidates and understanding disease mechanisms.
Jeffrey J. Whyte is a researcher who has published extensively on topics related to swine genetics, cloning, and using pig models for human diseases. Some of his publications include studies looking at using zinc finger nucleases and CRISPR to genetically modify pigs, producing cloned knockout pig models, and investigating cytokines and placental development in pigs. He has also researched using pig models to study cardiovascular conditions in humans.
This curriculum vitae summarizes the educational and professional background of Todd H. Ahern, PhD. It includes his postdoctoral training at the University of Massachusetts, Amherst, and PhD from Emory University. Dr. Ahern is currently an Assistant Professor at Quinnipiac University where he teaches courses in psychology and neuroscience. His research focuses on how early life social environments influence long-term social behaviors using rodent models like prairie voles. He has published several peer-reviewed articles and mentored numerous undergraduate students in his research laboratory.
1) The document discusses vitamin D deficiency and its link to various health issues. It reports that 61-82% of postmenopausal women and 98% of patients with osteoporotic fractures have inadequate vitamin D levels.
2) Several causes of vitamin D deficiency in the elderly are described, including lack of sun exposure and less effective vitamin D synthesis in the skin.
3) The text reviews results from studies that show vitamin D supplementation can reduce fracture risk by 33%, falling risk by 49%, and improve lower limb function. It is suggested that maintaining higher vitamin D levels may provide significant economic savings in healthcare costs.
Research on Multiple Chemical Sensitivity - Resources for Healthy Children www.scribd.com/doc/254613619 - For more information, Please see Organic Edible Schoolyards & Gardening with Children www.scribd.com/doc/254613963 - Gardening with Volcanic Rock Dust www.scribd.com/doc/254613846 - Double Food Production from your School Garden with Organic Tech www.scribd.com/doc/254613765 - Free School Gardening Art Posters www.scribd.com/doc/254613694 - Increase Food Production with Companion Planting in your School Garden www.scribd.com/doc/254609890 - Healthy Foods Dramatically Improves Student Academic Success www.scribd.com/doc/254613619 - City Chickens for your Organic School Garden www.scribd.com/doc/254613553 - Huerto Ecológico, Tecnologías Sostenibles, Agricultura Organica www.scribd.com/doc/254613494 - Simple Square Foot Gardening for Schools - Teacher Guide www.scribd.com/doc/254613410 - Free Organic Gardening Publications www.scribd.com/doc/254609890 ~
Nearly 1.4 million individuals suffer from traumatic brain injury (TBI) each year, leaving many survivors with significant deficits. Early and adequate nutrition support is challenging but may improve outcomes for TBI patients. The document discusses the metabolic and immune alterations caused by TBI and recommends enteral nutrition over parenteral nutrition when possible. It emphasizes starting nutrition within 48 hours and achieving full caloric needs by day 7 to prevent protein breakdown and support recovery. Barriers to providing nutrition like feeding intolerance are also reviewed.
Nearly 1.4 million individuals suffer from traumatic brain injury (TBI) each year, leaving many survivors with significant deficits. Early and adequate nutrition support is challenging but may improve outcomes for TBI patients. The document discusses the metabolic and immune alterations caused by TBI and recommends enteral nutrition over parenteral nutrition when possible. It emphasizes starting nutrition within 48 hours and achieving full caloric needs by day 7 to prevent protein breakdown and support recovery. Barriers to providing nutrition like feeding intolerance are also reviewed.
The document discusses the possible causes of rheumatoid arthritis (RA) based on research evidence. The immune system, specifically the innate immune response involving macrophages and dendritic cells, plays an important role in the development of RA by causing inflammation and destroying joints. Genetics also contribute, as RA has been linked to chromosome 6. Some studies have found historical evidence suggesting an infectious agent may promote RA. Environmental factors like smoking, low vitamin D levels, diet, and cold weather have also been associated with increased risk or severity of RA. Understanding the causes of RA could help improve treatment and management of the disease.
This document lists 21 publications and abstracts authored by Nino G. Joy, MD. The publications focus on research investigating the effects of hypoglycemia and hyperglycemia on markers of endothelial function, inflammation, and atherothrombosis in both healthy individuals and those with diabetes. Many of the studies examine the acute physiological responses to induced hypoglycemic or hyperglycemic conditions. The publications span the years 2010 to 2016 and were published in journals like Diabetes, the Journal of Diabetes Complications, and Metabolism.
Stress is defined as a state of physiological or psychological strain caused by an adverse stimuli , physical, mental, or emotional, internal or external that tend to disturb the functioning of an organism and which the organism naturally desires to avoid.
This document discusses possible links between vitamin D deficiency and various geriatric syndromes and common comorbidities. It begins by outlining how vitamin D receptors are present in many tissues beyond the musculoskeletal system. It then examines potential associations between vitamin D deficiency and increased risks of frailty, urinary incontinence, dementia/cognitive impairment, and depression in elderly populations. While evidence is limited and relationships are not clearly causal, several observational studies have found correlations between low vitamin D levels and higher rates of these conditions. More research is still needed, but maintaining adequate vitamin D status may help reduce risks of age-related diseases and functional decline.
Ibogaine is a psychoactive substance found in plants that has been studied for its effects in treating addiction. The most researched effect is its ability to reduce or eliminate addiction to opioids by alleviating withdrawal symptoms. Research also indicates it may be useful for treating alcohol, methamphetamine and nicotine addiction, as well as compulsive behaviors. However, more systematic clinical research is still needed. Some organizations like MAPS are studying ibogaine's long term effects and safety through observational studies. Ibogaine treatment is accompanied by counseling and potential relapse requires multiple treatment sessions over 12-18 months. Ibogaine carries some risks but may help address the unmet need for effective addiction treatments.
This document summarizes research on primary immunodeficiencies that cause increased susceptibility to fungal infections. It describes how innate and adaptive immunity normally defend against fungi through pattern recognition receptors, cytokines, and T cell responses. Deficiencies in the CARD9 protein, STAT1 and STAT3 genes, and the IL-17 and IL-22 pathways are highlighted as causing chronic mucocutaneous candidiasis by impairing Th17 responses. Autoantibodies against IL-17 and IL-22 in autoimmune polyendocrine syndrome type I can also phenocopy these genetic defects. Understanding these immunodeficiencies provides insight into antifungal immunity and opportunities for new therapies.
Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphoryla...Mahmoud Lotfy Soliman
Caffeine may help reduce Alzheimer's disease pathology associated with HIV infection by blocking the effects of the HIV protein Tat. The study found that:
1) HIV Tat increased amyloid-beta and phosphorylated tau levels in neural cells, markers of Alzheimer's disease, but caffeine prevented these increases.
2) HIV Tat disrupted endolysosome function in neural cells, but caffeine blocked these effects of Tat and preserved normal endolysosome functioning.
3) Caffeine on its own decreased amyloid-beta levels and may help protect against Alzheimer's disease progression in people living with HIV through its effects on endolysosome function and Tat protein activity.
Vitamina D ed Asma - Prof. Boner Attilio Università di VeronaRoberto Conte
1) Several studies show high rates of vitamin D deficiency and insufficiency among children with asthma. Low vitamin D levels are associated with worse asthma control, including increased exacerbations and hospitalizations.
2) Observational studies link higher maternal vitamin D intake during pregnancy to lower rates of wheezing and asthma in offspring. However, the evidence for a causal relationship is still insufficient.
3) Maintaining adequate vitamin D levels, especially during pregnancy and childhood, may help reduce asthma risk and severity by supporting lung development and function. Further research is still needed.
This document lists 48 original publications by JC Möller and collaborators related to Parkinson's disease, multiple system atrophy, restless legs syndrome, and other movement disorders. The publications cover a range of topics including experimental pain sensitivity, clinical decision making tools for chronic pain patients, roles of cortical and pallidal brain frequencies, association between sleep and dyskinesia in an animal model of Parkinson's, and several genetic studies related to various movement disorders.
Endocrine Disruption and Immune DysfunctionDES Daughter
by the Collaborative on Health and the Environment
On this first in a series of calls on endocrine disrupting chemicals, Dr. Rodney Dietert discussed how the immune system is a target for endocrine disrupting chemicals, particularly during development. Numerous relatively ‘hidden’ effects can ensue from a single risk factor and emerge over a lifetime. He also discussed how current safety testing fails to appropriately assess misregulated inflammation as the greatest immune based health risk.
Sources: http://www.healthandenvironment.org/partnership_calls/13389
This webinar discusses immunometabolism and its relationship to COVID-19. It explores how elevated glucose levels can favor SARS-CoV-2 infection by inducing viral replication and cytokine expression through a HIF-1α/glycolysis pathway. Insulin treatment is also discussed and its association with increased mortality in COVID-19 patients with diabetes. The role of mitochondria in producing reactive oxygen species during infection is covered, as is the potential for antioxidants and dietary changes like ketogenic diets to impact the immune response. Biomarkers of immunometabolism are proposed for monitoring clinical outcomes.
1. The document lists 29 publications with the author Lu Y, demonstrating their expertise in biomedical research related to neurodegenerative diseases and therapeutic antibody development.
2. Many of the publications focus on characterizing antibody delivery across the blood-brain barrier and targeting proteins involved in diseases like Alzheimer's.
3. The publications span from 2004 to the present and represent collaborative work with numerous co-authors investigating topics like antibody pharmacokinetics and biomarkers.
This document is a curriculum vitae for Dr. Avi L. Friedlich summarizing his personal and educational background, academic positions held, research support and medical certification, professional memberships, honors and awards, publications, and editorial experience. It details that he received a B.S. from UCLA and an M.D. from Case Western Reserve University, held various academic and research positions at institutions including Harvard Medical School and MIT, has over 50 publications in peer-reviewed journals, and has received several honors and awards for his research work.
This document lists invited presentations, publications, and patent applications by Rikki Alexander related to pharmaceutical research. It includes presentations on phosphodiesterase inhibitors for asthma treatment from 2002-2003. It also lists several patent applications and publications from 2008-2015 on small molecule inhibitors for conditions like TNF activity and PI3 kinase. The publications involve collaborations and are focused on developing drug candidates and understanding disease mechanisms.
This document provides a bibliography of journal publications and abstracts authored by Gregory S. Hamilton, Ph.D. It lists 34 journal publications from 1986 to 2006 on topics including organic synthesis, glutamate receptor antagonists, neurotrophic agents, and immunophilin ligands. It also lists 7 conference abstracts from 1988 to 1995 on related topics.
This document provides a publication list containing papers (6) and patents (5) with Lee W. Page as an author. The papers include articles published in Tetrahedron Letters, Chem. Commun., Bioorganic & Medicinal Chemistry Letters, and Acta Crystallographica Section C and cover topics such as synthesis of fused bicyclic isoxazoles, amination of allenes, CB2 agonists for pain treatment, and COX-2 inhibitors. The patents relate to preparation of compounds for use as calcium channel or cannabinoid receptor modulators.
Botulinum toxin, derived from Clostridium botulinum, has been approved by the FDA to treat various neurological conditions. Recent studies have found it may also help treat various types of neuropathic pain when injected into painful areas. Common sites of injection include locations of post-herpetic neuralgia, trigeminal neuralgia, and diabetic neuropathy. While protocols vary, typical doses range from 2.5 to 50 units injected at 1-40 sites. Adverse effects are generally mild, including neck pain, injection site pain, and eyelid ptosis in some cases.
The document summarizes the research of Prof. Chieh-Hsi Wu, who focuses on pathological mechanisms involved in restenosis progression and evaluations of bioactive compounds for treating restenosis, hyperlipidemia, and cancer. His laboratory uses genomic and proteomic analyses to identify molecules involved in restenosis development and potential therapeutic targets. He evaluates natural compounds for preventing restenosis and hyperlipidemia.
This document provides a summary of the professional experience and qualifications of Zoya Gluzman-Poltorak. It lists her contact information and includes a detailed list of over 30 peer-reviewed publications in scientific journals related to hematology, oncology, and radiation medicine spanning from 1997 to 2015. The publications demonstrate her expertise in areas such as hematopoietic recovery after radiation exposure, the effects of cytokines like interleukin-12, and the role of proangiogenic factors in cancer progression.
Daryl Walter has authored or co-authored 30 publications and patents from 2006 to 2009 related to pharmaceutical research. His publications focus on developing treatments for conditions like Alzheimer's disease, pain, and inflammation by modulating the P2X7 receptor and developing BACE-1 inhibitors. His work involved synthesizing new classes of drug-like molecules and characterizing their pharmacological properties.
Daryl Walter is an expert in drug discovery and development, with publications and patents spanning various therapeutic areas. Some of his work includes:
1) Developing novel P2X7 receptor modulators to treat pain and neurodegeneration through publications characterizing the receptor and novel chemical classes acting on it.
2) Discovering new BACE-1 inhibitors for Alzheimer's through structure activity relationship studies leading to drug candidates with improved potency and pharmacokinetics.
3) Designing and synthesizing novel heterocyclic chemical scaffolds and optimizing drug-like properties through medicinal chemistry.
Daryl Walter has authored or co-authored 34 publications and patents related to P2X7 receptor modulators and BACE-1 inhibitors. The publications describe the synthesis and testing of various chemical derivatives to modulate the P2X7 receptor, including imidazoles, pyrazoles, piperazines, and morpholines. Additional work involved optimizing hydroxyethylamine inhibitors of the BACE-1 enzyme for treatment of Alzheimer's disease.
The document provides information on several professors and their research areas at College of Pharmacy. It includes the names and areas of research for Professors Jing-Ping Liou, Chieh-Hsi Wu, Shawn Hsiang-Yin Chen, Wei-Chiao Chang, Jen-Ai Lee, David Hui-Wen Cheng, and Tzu-Hua Wu. The research areas include medicinal and organic chemistry, cardiovascular and cancer pharmacology, clinical pharmacy, pharmacogenomics, bioanalytical chemistry, pharmaceutical management and regulatory affairs, and clinical pharmacy and therapeutics. It also lists some representative publications for each professor.
This document lists posters presented from 1997-2010 related to gene expression analysis, toxicity mechanisms, drug screening, and steroid receptor activity. Key topics covered include stable expression of genes related to absorption, distribution, metabolism and toxicity of compounds in precision cut human liver slices; development of luciferase reporter assays in HepG2 cells to assess genotoxicity and oxidative stress; screening of selective estrogen receptor modulators and androgen receptor modulators; comparison of human estrogen receptor alpha and beta; and hormonal properties of progestins and norethisterone derivatives. The posters were presented at various conferences between 1997-2010.
Lindsay Jordan has over 15 years of experience in the pharmaceutical industry, specializing in immunology techniques including cell culture, molecular biology, and ELISA development. She has worked at Biothera Pharmaceuticals since 2007 where she developed and validated potency assays, authored SOPs, and supported clinical trials. Prior to this, she held positions at 3M Pharmaceuticals and ViroMED Laboratories, optimizing assays and discovering drug mechanisms of action. Jordan has a Bachelor's degree in Biology and is proficient in laboratory techniques and data analysis software. She has authored multiple publications and presentations on topics including beta-glucan immunology and cancer immunotherapy.
This document provides biographical and professional information about Dr. John L. Clayton. It lists his education, including receiving an MD from Louisiana State University in 2005, a PhD in Epidemiology from Tulane University in 2001, and an MPH from Tulane University in 1998. It outlines his medical training, including an internship in general surgery at UCLA from 2005-2006, a residency in general surgery at UCLA from 2006-2010, and a residency in plastic and reconstructive surgery at UNC Hospitals from 2010-2013. It also lists his board certifications, work experience, research publications, and presentations.
This document contains 57 references cited on 3 pages. The references are studies and literature on topics related to nutrition and hair health, including fatty acids, calcium, iron, and proteins. Many of the references examine the role of nutrients like omega-3 fatty acids, calcium, iron, and proteins from foods like sardines on outcomes like hair loss, skin health, obesity, and metabolic syndrome.
This document contains 53 bibliographic references related to sardine protein and its effects. The references are studies on topics like:
- Nutritional deficiencies and hair loss
- Effects of sardine protein on insulin resistance, inflammation and oxidative stress
- Role of omega-3 fatty acids, calcium, and other nutrients in skin and hair health
- Impact of diet on conditions like atopic dermatitis, psoriasis, and photoaging
¿Cómo funciona?
Según científicos del Instituto Himalaya de Ciencias Médicas, la pérdida de audición ocurre cuando el tímpano pierde elasticidad debido a la inflamación desencadenada por el sistema inmunológico del cuerpo cuando se expone a una nueva amenaza.
Esta nueva amenaza proviene de productos químicos médicos tóxicos (u ototoxinas) que desafortunadamente pueden ser Se encuentra en la mayoría de los medicamentos recetados diariamente por los médicos sin saberlo.
Al abordar la causa raíz de la pérdida auditiva, SonoFit actúa como un "vendaje en el oído interno", calmante y ayudando al tímpano a recuperarse, mientras lo protege de daños futuros.
This document lists 41 publications authored or co-authored by Himadri Samanta from 1977 to 2007. The publications cover research conducted by Samanta and collaborators on topics including thymineless death in Escherichia coli, radiation response of thymine starved bacteria, interferon action and the enzymology of interferon pathways, expression of hepatitis B virus antigens, characterization of recombinant enzymes expressed in cell lines, analysis of drug-resistant HIV strains, and discovery of new classes of HIV integrase inhibitors.
1. Appendix: Publications
1. Preparation of heteroaryl compounds as Kynurenine-3-monooxygenase
inhibitors for treatment of neurodegenerative disorders. Dominguez, Celia;
Toledo-Sherman, Leticia M.; Prime, Michael; Mitchell, William; Went, Naomi; PCT
Int. Appl. (2015), WO 2015047978 A1 20150402.
2. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and
methods of use. Dominguez, Celia; Toledo-Sherman, Leticia M.; Prime,
Michael; Mitchell, William; Went, Naomi; PCT Int.
Appl. (2015), WO 2015047982 A2 20150402.
3. Development of a Seriesof Aryl Pyrimidine Kynurenine Monooxygenase
Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s
Disease, Toledo-Sherman, L.M.; Prime, M. E.; Mrzljak, L.; Beconi, M. G.;
Beresford, A.; Brookfield, F. A.; Brown, C. J.; Cardaun, I.; Courtney, S.M.;
Dijkman, U.; Hamelin-Flegg, E.; Johnson, P. D.; Kempf, V.; Lyons, K.; Matthews, K.;
Mitchell, W. L.; O’Connell, C.; Pena, P.; Powell, K.; Rassoulpour, A.; Reed, L.;
Reindl, W.; Selvaratnam, S.; Friley, W. W.; Weddell, D. A.; Went, N. E.; Wheelan, P.;
Winkler, C.; Winkler, D.; Wityak, J.; Yarnold, C. J.; Yates, D.; Munoz-Sanjuan, I.;
Dominguez, C.; J. Med. Chem., 2015, 58,1159–1183.
4. CHDI-00340246, A Kynurenine Monooxygenase Inhibitor as Potential
Therapeutic Agent for the Treatment of Huntington’s Disease. Toledo-Sherman,
L. M.; Prime, M.; Mitchell, W.; Brown, C.J.; Gaines, S.; Johnson, P.; Pena, P.; Reed,
L.; Sehmi, S.; Selvaratnam, S.; Winkler, D.; Beconi, M.; Lyons, K.; Rassoulpour, A.;
Dijkman, U.; Powell, K.; Ward, W.; Kempf, V.; Wheelan, P.; Yates, D.; Matthews, K.;
Mrzljak, L.; Munoz-Sanjuan, I.; Dominguez, C.; Journal of Neurology Neurosurgery &
Psychiatry 09/2014; 85(Suppl 1):A2-A3.
5. Preparation of phenylcyclopropyl carboxylic acids and similar compounds as
kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions
containing same, and use in treating neurodegenerative disorders. Toledo-
Sherman, L. M.; Dominguez, C.; Prime, M.; Mitchell, W. L.; Johnson, P.; Went, N.;
World Patent 2013151707 (2013).
6. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-
secretase modulators reduced amyloidogenic Aβ peptides in vivo. Huang, Y.; Li,
T.; Eatherton, A.; Mitchell, W. L.; Rong, N.; Ye, L.; Yang, X-J.; Jin, S.; Ding, Y.;
Zhang, J.; et al; Neuropharmacology, 2013, 70, 278-286.
7. Preparation of phenylpyrimidinylcarboxylic acid derivatives and analogs for
use as kynurenine-3-monooxygenase inhibitors. Courtney, S. M.; Prime, M.;
Mitchell, W.; Brown, C. J.; De Aguiar Pena, P. C.; Johnson, P.; Dominguez, C.;
Toledo-Sherman, L. M.; Munoz, I.; PCT Int.
Appl. (2013), WO 2013033085 A1 20130307
8. Preparation of phenylpyrimidine derivatives and analogs for use as kynurenine -
3-monooxygenase inhibitors. Courtney, S. M.; Prime, M.; Mitchell, W.; Brown, C.
J.; De Aguiar Pena, P. C.; Johnson, P.; Dominguez, C.; Toledo-Sherman, L. M.;
Munoz, I.; PCT Int. Appl. (2013), WO 2013033068 A1 2013030725.
9. Certain pyrimidine derivatives as kynurenine-3-monooxygenase inhibitors,
pharmaceutical compositions, and methods of use and preparation thereof
Dominguez, C.; Toledo-Sherman, L. M.; Courtney, S. M.; Prime, M.; Mitchell, W.;
Brown, C. J.; De Aguiar Pena, P. C.; Johnson, P.; PCT Int. Appl. (2013),
2013016488 A1 20130131.